Venaxis, Inc. announced that it has begun enrolling patients into its pivotal clinical study in the United States. Based on current enrollment expectations, the company anticipates completing the study in six to eight months and filing with the FDA for regulatory clearance of APPY1 in the fourth quarter 2013.